VIRGINIAMYCIN MARKET ANALYSIS
Virginiamycin Market- Competitive Analysis
Key players in the market are focused on development, manufacturing, and marketing of multisource and branded pharmaceuticals, thereby augmenting the market growth. For instance, in January 2017, Huvepharma AD received approval for STAFAC (virginiamycin) plus CLINACOX (diclazuril) combination drug type in chickens for prevention of necrotic enteritis and coccidiosis in broiler chickens.
Key players operating in the global virginiamycin market include, Hongcong Xinrunde Chemical Co., Ltd, Xiamen ShengLang SaiChuang Biological Technology Co., Ltd., Manus Aktteva Biopharma, Alfanzyme, Phibro Animal Health Corporation, Merck Animal Health, Zoetis, Elanco, Virbac, Ceva, and Vetoquinol.
Virginiamycin Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients